Champions OncologyCSBR
CSBR
About: Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
Employees: 306
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
2,033% more call options, than puts
Call options by funds: $192K | Put options by funds: $9K
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
74% more capital invested
Capital invested by funds: $28.2M [Q3] → $49M (+$20.8M) [Q4]
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
9% more funds holding
Funds holding: 22 [Q3] → 24 (+2) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
1.18% less ownership
Funds ownership: 42.56% [Q3] → 41.38% (-1.18%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$12
52%
upside
Avg. target
$12
52%
upside
High target
$12
52%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Craig-Hallum Matt Hewitt 52% 1-year accuracy 12 / 23 met price target | 52%upside $12 | Buy Maintained | 12 Mar 2025 |
Financial journalist opinion
Neutral
Seeking Alpha
1 month ago
Champions Oncology, Inc. (CSBR) Q3 2025 Earnings Call Transcript
Champions Oncology, Inc. (NASDAQ:CSBR ) Q3 2025 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Conference Call Participants Maj Soueidan - GeoInvesting George Marema - Pareto Ventures Operator Greetings. Welcome to the Champions Oncology Third Quarter Fiscal Year 2025 Earnings Call [Operator Instructions].
Neutral
Accesswire
1 month ago
Champions Oncology Reports Record Quarterly Revenue of $17.0 Million Record Net Income of $4.5 Million
HACKENSACK, NJ / ACCESS Newswire / March 11, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its third quarter of fiscal 2025, ended January 31, 2025. Third Quarter and Recent Highlights: Total revenue increased 42% to $17.0 million Gross profit of $10.4 million; gross margin of 61% Net income of approximately $4.5 million Adjusted EBITDA of $5.2 million Signed first data licensing deal worth up to $8.0 million Hired Matt Newman, Executive Vice President and General Manager, to lead and expand the development of Champions' data licensing platform Year to Date Highlights: Total revenue increased 23% to $44.6 million Gross profit of $23.5 million; gross margin of 53% Net income of $6.5 million Adjusted EBITDA of $8.3 million Ronnie Morris, CEO of Champions, commented, "Our third quarter was transformational, marked by our first major data licensing agreement-an important milestone toward monetizing our proprietary data platform.
Neutral
Accesswire
1 month ago
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 11, 2025
HACKENSACK, NJ / ACCESS Newswire / March 6, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the third quarter ended January 31, 2025, on Tuesday, March 11, 2025, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
Neutral
Accesswire
2 months ago
Champions Oncology Announces 17 Abstracts Accepted for Presentation at the 2025 American Association for Cancer Research Annual Meeting
HACKENSACK, NJ / ACCESS Newswire / February 18, 2025 / Champions Oncology Inc. (NASDAQ:CSBR), a global leader in preclinical oncology research and clinical specialty testing, today announced the acceptance of seventeen abstracts for presentation at the AACR Annual Meeting, in Chicago, IL (April 25-30, 2025). These presentations will highlight Champions' cutting-edge research, featuring innovative in vivo and organoid platforms for oncology and immuno-oncology drug testing, as well as AI-driven models that utilize multi-omics datasets to predict patient outcomes.
Neutral
Accesswire
3 months ago
Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership
HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy. The addition of Cytek Aurora instruments elevates Champions' service offerings, building on its already competitive spectral and conventional flow cytometry capabilities.
Neutral
Seeking Alpha
3 months ago
Champions Oncology: Right Point To Own In The Cycle Thanks To Operating Efficiencies
Champoins Oncology broke out of a multiyear downtrend following its Q2'25 earnings. Management has embarked on a one-way journey to reduce working capital and grow the business with zero incremental capital. This has succeeded and the business is now in a prime position to grow sales at 10% CAGR to CY'26 in my opinion.
Neutral
Seeking Alpha
4 months ago
Champions Oncology, Inc. (CSBR) Q2 2025 Earnings Call Transcript
Champions Oncology, Inc. (NASDAQ:CSBR ) Q3 2024 Earnings Conference Call December 11, 2024 4:30 PM ET Company Participants Ronnie Morris - Chief Executive Officer David Miller - Chief Financial Officer Operator Greetings. Welcome to the Champions Oncology Second Quarter Fiscal Year 2025 Earnings Call.
Neutral
Accesswire
4 months ago
Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million
HACKENSACK, NJ / ACCESSWIRE / December 11, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its second quarter of fiscal 2025, ended October 31, 2024. Second Quarter and Recent Highlights: Total revenue increased 17% to $13.5 million Gross profit of $6.1 million; margin of 45% Net income of approximately $730,000 Adjusted EBITDA of $1.1 million Development of new data revenue stream First Half 2025 Highlights: Total revenue increased 14% to $27.6 million Gross profit of $13.1 million; margin of 47% Net income of $2.1 million Adjusted EBITDA of $3.2 million Ronnie Morris, CEO of Champions, commented, "Our second quarter's performance solidified our confidence in the Company's turnaround that we've been discussing the last several quarters.
Neutral
Accesswire
4 months ago
Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024
HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2024, on Wednesday, December 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
Neutral
Accesswire
6 months ago
Champions Oncology Announces Agreement with Weill Cornell Medicine
HACKENSACK, NJ / ACCESSWIRE / October 16, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a leader in the development of advanced preclinical oncology solutions, is pleased to announce a licensing agreement with Weill Cornell Medicine through the Center for Technology Licensing (CTL), part of Enterprise Innovation at Weill Cornell Medicine. This strategic collaboration will allow Champions Oncology to distribute and commercialize Weill Cornell Medicine's extensive bank of hematological patient-derived xenograft (PDX) models, generated by Dr. Giorgio Inghirami, Professor of Pathology and Laboratory Medicine at the institution and a member of the Englander Institute for Precision Medicine and Sandra and Edward Meyer Cancer Center.
Charts implemented using Lightweight Charts™